SNMMI 2025 Annual Meeting
Get the latest research and practical clinical applications from the SNMMI 2025 Annual Meeting, including focused coverage on genitourinary cancer data.
Dr. Flavell discusses how landmark studies have shaped current trial designs, and growing interest in combination therapies.
Dr. Flavell highlights the expansion of lutetium PSMA therapies into earlier disease settings: HSPC and oligometastatic PC.
Preliminary trial data suggests that 18F-DCFPyL PSMA PET/CT combined with mpMRI may improve csPCA detection over MRI alone.
Quantitative analysis outperformed visual analysis in the prediction of outcomes for patients undergoing Lu-PSMA therapy.
![Monitoring [177Lu]Lu-PSMA Therapy in mCRPC: Clinical Protocols](https://mumcdnstorage.blob.core.windows.net/guonc/2022/09/Metastatic-prostate-cancer.jpg)
New research explores the prognostic potential of LuPSMA-SPECT/CT with RECIP 1.0 in patients with advanced prostate cancer.
Researchers investigated the use of PSMA PET-CT to determine treatment options for patients with biochemical failure in PC.
18F-fluciclovine PET detected disease in more than half of the study’s patients with BCR and negative PSMA PET results.
Advertisement
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.